- Home
- AOSL vs MLYS Comparison
AOSL vs MLYS Comparison
Compare AOSL & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOSL
- MLYS
- Stock Information
- Founded
- AOSL 2000
- MLYS 2019
- Country
- AOSL United States
- MLYS United States
- Employees
- AOSL N/A
- MLYS N/A
- Industry
- AOSL Semiconductors
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- AOSL Technology
- MLYS Health Care
- Exchange
- AOSL Nasdaq
- MLYS Nasdaq
- Market Cap
- AOSL 768.5M
- MLYS 893.0M
- IPO Year
- AOSL 2010
- MLYS 2023
- Fundamental
- Price
- AOSL $21.76
- MLYS $14.65
- Analyst Decision
- AOSL Buy
- MLYS Strong Buy
- Analyst Count
- AOSL 3
- MLYS 3
- Target Price
- AOSL $32.33
- MLYS $33.00
- AVG Volume (30 Days)
- AOSL 553.0K
- MLYS 650.3K
- Earning Date
- AOSL 05-07-2025
- MLYS 05-12-2025
- Dividend Yield
- AOSL N/A
- MLYS N/A
- EPS Growth
- AOSL N/A
- MLYS N/A
- EPS
- AOSL N/A
- MLYS N/A
- Revenue
- AOSL $680,974,000.00
- MLYS N/A
- Revenue This Year
- AOSL $5.32
- MLYS N/A
- Revenue Next Year
- AOSL $6.62
- MLYS N/A
- P/E Ratio
- AOSL N/A
- MLYS N/A
- Revenue Growth
- AOSL 3.57
- MLYS N/A
- 52 Week Low
- AOSL $15.90
- MLYS $8.24
- 52 Week High
- AOSL $53.29
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- AOSL 54.29
- MLYS 53.36
- Support Level
- AOSL $19.25
- MLYS $14.03
- Resistance Level
- AOSL $22.70
- MLYS $15.79
- Average True Range (ATR)
- AOSL 1.22
- MLYS 0.99
- MACD
- AOSL 0.66
- MLYS 0.10
- Stochastic Oscillator
- AOSL 85.36
- MLYS 57.57
About AOSL Alpha and Omega Semiconductor Limited
Alpha & Omega Semiconductor Ltd designs, develops and supplies a portfolio of power semiconductors targeting various applications, including personal computers, flat-panel TVs, LED lighting, smartphones, battery packs, consumer and industrial motor controls and power supplies for TVs, computers, servers and telecommunications equipment. It generates revenue mainly from the sale of power semiconductors, consisting of power discretes and power ICs with a presence in Hong Kong, China, South Korea, the United States and other countries.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.